365 related articles for article (PubMed ID: 12480560)
1. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
Mas A; Rodés J; Sunyer L; Rodrigo L; Planas R; Vargas V; Castells L; Rodríguez-Martínez D; Fernández-Rodríguez C; Coll I; Pardo A;
J Hepatol; 2003 Jan; 38(1):51-8. PubMed ID: 12480560
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.
Williams R; James OF; Warnes TW; Morgan MY
Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):203-8. PubMed ID: 10741936
[TBL] [Abstract][Full Text] [Related]
3. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Pedretti G; Calzetti C; Missale G; Fiaccadori F
Ital J Gastroenterol; 1991 May; 23(4):175-8. PubMed ID: 1751811
[TBL] [Abstract][Full Text] [Related]
4. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
[TBL] [Abstract][Full Text] [Related]
5. Lactitol versus lactulose in the treatment of acute portal systemic encephalopathy (PSE). A controlled trial.
Heredia D; Caballería J; Arroyo V; Ravelli G; Rodés J
J Hepatol; 1987 Jun; 4(3):293-8. PubMed ID: 3598162
[TBL] [Abstract][Full Text] [Related]
6. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
[TBL] [Abstract][Full Text] [Related]
7. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
8. Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: antimicrobial activity, efficacy, and safety.
Williams R; Bass N
Rev Gastroenterol Disord; 2005; 5 Suppl 1():S10-8. PubMed ID: 15976747
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin for the treatment of hepatic encephalopathy.
Lawrence KR; Klee JA
Pharmacotherapy; 2008 Aug; 28(8):1019-32. PubMed ID: 18657018
[TBL] [Abstract][Full Text] [Related]
11. Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial.
Uribe M; Toledo H; Perez F; Vargas F; Gil S; Garcia-Ramos G; Ravelli GP; Guevara L
Dig Dis Sci; 1987 Dec; 32(12):1345-53. PubMed ID: 3319453
[TBL] [Abstract][Full Text] [Related]
12. Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
Miglio F; Valpiani D; Rossellini SR; Ferrieri A
Curr Med Res Opin; 1997; 13(10):593-601. PubMed ID: 9327194
[TBL] [Abstract][Full Text] [Related]
13. Prolonged remission from hepatic encephalopathy with rifaximin: results of a placebo crossover analysis.
Bajaj JS; Barrett AC; Bortey E; Paterson C; Forbes WP
Aliment Pharmacol Ther; 2015 Jan; 41(1):39-45. PubMed ID: 25339518
[TBL] [Abstract][Full Text] [Related]
14. Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO; Eaton-Maxwell A
Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
[TBL] [Abstract][Full Text] [Related]
15. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt.
Riggio O; Balducci G; Ariosto F; Merli M; Pieche U; Pinto G; Tremiterra S; Ziparo V; Capocaccia L
Dig Dis Sci; 1989 Jun; 34(6):823-9. PubMed ID: 2656134
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
17. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial.
Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F;
Hepatology; 2017 Feb; 65(2):592-603. PubMed ID: 27775818
[TBL] [Abstract][Full Text] [Related]
18. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.
Bajaj JS; Heuman DM; Wade JB; Gibson DP; Saeian K; Wegelin JA; Hafeezullah M; Bell DE; Sterling RK; Stravitz RT; Fuchs M; Luketic V; Sanyal AJ
Gastroenterology; 2011 Feb; 140(2):478-487.e1. PubMed ID: 20849805
[TBL] [Abstract][Full Text] [Related]
19. Lactitol vs. lactulose in the treatment of acute hepatic encephalopathy in cirrhotic patients: a double-blind, randomized trial.
Morgan MY; Hawley KE
Hepatology; 1987; 7(6):1278-84. PubMed ID: 3315932
[TBL] [Abstract][Full Text] [Related]
20. Treatment of porto-systemic encephalopathy with lactitol verus lactulose: a randomized controlled study.
Pai CH; Huang YS; Jeng WC; Chan CY; Lee SD
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jan; 55(1):31-6. PubMed ID: 7712392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]